The CSL (ASX:CSL) share price has gained 14% in the last 6 months

Here's what's been driving the CSL share price lately.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Limited (ASX: CSL) share price has gained 14.36% over the last 6 months, despite limited news having been released by the company.

However, the period has been a busy one for CSL, as detailed in its financial year 2021 results which dropped last week.

Right now, the CSL share price is $306.91, having gained 0.26% today.

Let's take a closer look at what CSL has been up to over the past 6 months.

The 6 months just gone for CSL

The CSL share price is currently a whopping 14% higher than it was exactly 6 months ago, despite the company having been relatively quiet. Indeed, the most exciting news from CSL was also its most recent.

CSL released its full-year report to the market on Wednesday last week. Over the financial year 2021, CSL's revenue increased 9.6% and its profit after tax boosted 10% higher.

Additionally, the company increased its final dividend by 10% to US$2.22 per share.

While the CSL share price initially fell 1.4% on its FY21 results, it has gained since 4.5%.

The only other time the ASX heard price-sensitive news from CSL during the last 6 months was in May when the company announced it was to acquire the rights for etranacogene dezaparvovec (AMT-061), a late-stage haemophilia B treatment.

The deal saw CSL pay Uniqure NV US$450 million for the rights. CSL also agreed to provide milestone royalty payments to Uniqure.

Additionally, as The Motley Fool Australia recently reported, CSL's gains could have been helped along by its candidacy in potentially producing mRNA vaccines in Australia, or the Australian dollar's strength against that of the US.

CSL share price snapshot

The last 6 months have seen the CSL share price perform a strong upturn.

Right now, it is 8.3% higher than it was at the start of 2021. It is also 3.8% higher than it was this time last year.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Researchers and doctors with futuristic 3d hologram overlay for body anatomy or dna in hospital clinic.
Healthcare Shares

Why investors are watching this ASX healthcare stock

A fresh clinical update has been released.

Read more »

A Sonic Healthcare medical researcher wearing a white coat sits at her desk in a laboratory conducting a COVID-19 test
Healthcare Shares

This biotech is up more than 20% on new deal news

Revenue will flow under this global deal just announced.

Read more »

A male doctor and a woman in scrubs in the foreground smile.
Healthcare Shares

The next 3 years could be huge for this ASX healthcare stock. Here's why

Today's update has put this ASX healthcare stock back in the spotlight as investors reassess its long-term growth potential.

Read more »

A doctor sits with a patient and uses a pen to point to certain parts of her mammogram scan
Healthcare Shares

Top broker says this ASX small-cap healthcare stock could be set to double

This company is making significant clinical and commercial progress .

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

3 quality ASX healthcare shares worth buying now

Brokers think the tide is turning for these battling medical heavyweights.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

Early success in battling Crohn's Disease has sent this ASX biotech's shares soaring

The early-stage results have been described as outstanding.

Read more »

Medical workers examine an xray or scan in a hospital laboratory.
Healthcare Shares

Why are 4DMedical shares in a trading halt today?

The company is looking to raise fresh capital.

Read more »

Medical workers examine an xray or scan in a hospital laboratory.
Healthcare Shares

This ASX biotech's shares are up strongly on good news out of the US

The addressable market for this newly approved software is huge.

Read more »